Dr. Meredith Halks Miller is a physician-scientist, Board Certified in Anatomic & Neuropathology. She started her career as an Assistant Professor at UCSF, doing research in neurotoxicology and brain injury models. She later joined Berlex Biosciences, a subsidiary of Schering AG, where she established the unit of Pharmacopathology to bring clarity and efficiency to analysis of histopathologic changes in early stage studies for drug development. After Berlex, Meredith became the CLIA Laboratory Director at Pathwork Diagnostics, a cutting-edge molecular diagnostics company that analyzed RNA from cancer tissue samples to predict the tissue of origin for cancers of uncertain primary. From there, she joined Verinata (Illumina) as Laboratory Director. Verinata had developed a test which used next generation sequencing to screen for fetal trisomies in maternal blood. At Verinata, she made the seminal observation that maternal malignancies could be detected from sequencing abnormalities in plasma cfDNA. That discovery led to the formation of GRAIL, where she served as the founding laboratory director. After retiring from GRAIL, Dr. Halks Miller consulted for various CLIA laboratories. She currently serves on two Scientific Advisory Boards.
Dr Halks Miller did her residency training at Stanford and at UCSF. She received both her MD and AB (physics) degrees from Boston University. Before attending Boston University, she completed the Freshman Foundation program at the Rhode Island School of Design.